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pl4ARF: A p53-independent Tumor Suppressor
by
Monte W. Miller
Doctor of Philosophy, Graduate Program in Biochemistry 
Loma Linda University, December 2004 
Dr. Penelope Duerksen-Hughes, Chairperson
Many genetic alterations at the CDKN2A locus on human chromosome 9
have been shown to be at least partially responsible for transformation of cells to
a cancerous phenotype. This locus encodes two proteins, p!6 and p!4, that play
a pivotal role in tumor surveillance.
Breakdowns in the p!4 pathway have been estimated to be present in
approximately 40% of human cancers and only recently have its binding partners
and effects begun to be defined. Its interaction with the p53 pathway, which is
estimated to be inactivated or mutated in 50% of all cancers, makes it difficult to
determine its own independent effects, but also makes it a prime target for
cancer intervention. Taken together, one or both of these pathways have been
estimated to be aberrant in virtually all human cancers, therefore, understanding
their individual and cooperative effects may prove to be of paramount
importance.
vii
In the present study we evaluated the overexpression of the p!4ARF tumor 
suppressor in the cancerous HCT116 parent cell line along with its p53 knockout
derivative. Our results indicate that p!4 indeed has a very potent effect in the
presence of p53, and a substantial effect in its absence.
In the clonogenicity experiments p!4 had a very powerful affect, both in 
the presence and absence of p53. In the presence of p53, p!4 was able to
reduce the number of colonies grown by 98%, and in the absence of p53 it was
able to reduce the colony count by 83%. In the cell velocity assays, p!4 was
able to retard cell growth in high-density populations in the absence of p53.
Furthermore, p!4 was also able to reduce the size of tumors grown in nude mice 
by a substantial margin in the absence of p53.
These experiments demonstrate that p!4ARF has tumor suppressor activity
that is independent of the p53 pathway. ARF expression exhibited a more
profound affect on cell viability in the presence of p53, due to both tumor
suppressor pathways being active. However, even in the absence of p53, p!4
was able to mitigate the growth of cells both in vivo and in vitro.
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INTRODUCTION
The CDKN2A locus (INK4A/ARF locus) is located on human chromosome 9 
and encodes two proteins.1 Each is encoded by three exons with the latter two 
coding regions being shared. However, due to a frameshift in the coding frame,
the two proteins share no amino acid homology. The INK4A locus produces the
16 kDa protein pl6, which is 156 amino acids in length. The ARE locus produces 
a 14 kDa protein, pl4ARF. ARE was the second protein established as being
produced from the CDKN2A region, so it was designated Alternative Reading
Frame or ARE. It is 132 amino acids in length with exons ip and 2 contributing
all the amino acids in the protein. The region encompassing the three exons of
pl6 is about 7 kb, and it includes exons la, 2 and 3. The a/fgene consists of
three exons as well, exon ip, 2 and 3. Because exon ip is located approximately 
20 kb upstream from exon 2, the ARE locus encompasses about 30 kb (Fig. I).2
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Figure 1. Human Chromosome 9, locus CDKN2A. Two proteins are produced from this locus, pl6 and ARF. Both 
mRNAs share the coding regions of exons 2 and 3. pl6 is produced from an approximately 7 kb region and has 3 
exons, la, 2 and 3; it is transcribed into a 987 nucleotide mRNA, which is then translated into a 156 amino acid 
protein. ARF is produced from a frameshift in the coding sequence. Exon ip is approximately 20 kb upstream from 
exon 2. The 3 exons of ARF are transcribed from an approximately 30 kb region into a 1016 nucleotide mRNA, which 
is translated into a 132 amino acid protein.
The pl6 protein is known to be an inhibitor of the cell cycle through the 
retinoblastoma (Rb) pathway. Rb binds to transcription factors of the E2F family 
and inactivates them. These transcription factors are required to induce S-phase
in order for cells to divide; therefore, inactivation of the E2F family inhibits cell 
division.3 When the Rb protein is phosphorylated it releases the transcription
factors and cell division can take place. p!6 prevents this phosphorylation and 
helps keep cell division in check (Fig. 2).1,4
3
Cell Division
Figure 2. pl6 interaction with the retinoblastoma pathway. In the absence of pl6, the retinoblastoma protein is 
phosphorylated and releases the E2F family of transcription factors. Alternately, when p!6 is present, it helps prevent 
this phosphorylation and Rb inactivates the E2F's by remaining bound to them.
The gene is reportedly controlled at the transcriptional level. Its 
transcription can be induced in response to the mitogenic transcriptional factors 
Myc and E2F1-3.5,6,7'8 It can also be activated by ras, part of the intracellular 
signaling cascade which responds to extracellular stimuli.5,9 Additionally, ARF 
transcription can be induced by viral oncogenes E1A5,10 and v-abl.11 Conversely, 
ARF can be repressed by mammalian transcriptional repressors Bmi12, Tbx-2 13 
and Twist.5,14 Twist can act as a transcriptional activator or repressor, depending 
on its binding partners. For ARF however, it functions as a repressor. ARF 
promoter methylation, and subsequent silencing, is also reported in many 
cases.15 The mouse homolog for p!4ARF is pl9ARF and is widely reported on as 
well.16
The ARF protein is induced in response to several mitogenic signals and
has an overlapping three-pronged effect, stimulating the p53 pathway, other
direct targets, and changes in gene transcription (Table 1). The first effect is
controlled through its interaction with MDM2, by preventing MDM2 from causing 
the degradation of the senescence/apoptosis transcription factor p53.17 The 
second effect is accomplished through direct protein-protein binding and the 
translocation and/or the degradation of binding partners. Protein-protein 
interactions with transcription factors 18, DNA unraveling proteins 19, and cell 
cycle regulators7 have been reported. The third pl4ARF effect is produced by
indirectly causing changes in the cellular transcription activities. The transcription 
of genes related to the repression of cell division is activated 20, while the
5
































































changing of some transcriptional activators to repressors21 has also been 
reported. This three-pronged effect helps mitigate cell division and has been
shown to stop cells from dividing at both the Gi and G2 checkpoints.
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This locus, therefore, encodes two different proteins with no amino acid
homology that are known to be participants in two major tumor suppressor
pathways, namely the p53 and retinoblastoma pathways.
A general theme seen in studies on the activity of the ARF protein is its
ability to bind to and translocate other proteins to the nucleolus. The two regions
that have been reported as important for nucleolar localization and protein
binding are located between residues 2-14 (from exon Ip) and 82-101 (from 
exon 2).5 In another related study, three nucleolar localization signals were
proposed for ARF: residues 10-13 (RIRR), 87-90 (RRPR), and 96-99 (RARR), all 
similar to the known nucleolar localization motif R/K - R/K - X - R/K.22 Three
cysteine residues have been reported as important for homo-oligomerization.
(15,100, and 123), but whether they have biological relevance is not yet 
known.5
A great body of evidence over time has shown the connection between
the ARF protein and the p53 pathway via MDM2, its best characterized inhibitor.
p53 is a 53 kDa protein that is a transcription factor which integrates many
different cell signals and plays a pivotal role in both senescence and apoptosis.
Modifications of p53 by these signaling pathways can lead to cell-cycle arrest,
23,24 Hence, the loss of functional p53senescence, differentiation and apoptosis.
leads to an increased susceptibility to malignant progression.
The ARF protein is of great importance to the MDM2-p53 axis. p53
induces the transcription of MDM2, which binds to p53, ubiquitinates it, and
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causes its degradation in the cytoplasm, thus completing a negative feedback 
loop.17 pl4ARF binds to MDM2, translocates it to the nucleolus and inhibits its
ability to interact with p53, subsequently causing the concentrations of p53 to 
rise.22 The pH^ domain from amino acids 2-14 has been reported as sufficient 
to bind and relocalize MDM2 to the nucleolus. It has been reported that this
region is masked following binding to MDM2, but a cryptic nucleolar localization
signal in MDM2 is exposed by this interaction and causes the translocation of the 
proteins.22
Cell lines deficient in the ARF protein have been estimated to involve 
approximately 40%25 of human cancers, while breakdowns in the p53 pathway 
have been estimated to be present in 50%2 of all cancers. This is a powerful 
combination indeed, and together, one or both pathways have been estimated to 
be aberrant in virtually all human cancers.26
Recent evidence confirms that ARF also interacts with other targets not 
associated with p53 (Table 1). Among these are HIF-118, c-Myc6, topoisomerase 
119, several E2F transcription factors7, and B23.27 ARF also represses the cellular 
NF-AB response through its subunit RelA, and can cause it to become a 
repressor, rather than an activator, of anti-apoptosis genes.21 ARF has also been 
shown to activate Tobl and several members of the Btg family, a group of 
antiproliferative genes.20 These proteins are involved in an array of actions 
connected to rRNA processing, apoptosis, division, vascularization, and 
adaptation, which are all related to cell proliferation and tumor development.
8
HIF-1 (Hypoxia Inducible Factor) is a heterodimeric (a/p) transcription
factor that causes multiple genes to be transcribed in response to low oxygen 
concentration. In the presence of oxygen, HIF-la can be hydroxylated at proline 
residues 402 or 564, which marks it for proteosomal degradation.28 In the
absence of oxygen, HIF-la binds to the HIF-ip subunit and together they 
activate the transcription of genes related to neovascularization, metabolism, 
transport and adaptation, all of which are important to tumor angiogenisis.29 ARF
binds to the a-subunit of HIF-1 and sequesters it in the nucleolus and thus 
prevents HIF-1 activated transcription (Fig. 3).18
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Figure 3. HIF-1 degradation and activation. The HIF-1 transcription factor is activated by the dimerization of the a 
and (3 subunits. Alternately, HIF-1 is degraded after hydroxylation or inactivated by binding to ARF.
In addition, ARF binds to topoisomerase I, a DNA unraveling enzyme, and
sequesters it into the nucleolus, but does not inactivate it. In this setting
topoisomerase I loosens DNA in the nucleolus, which encodes mostly ribosomal 
RNA, for reasons that are still unclear.19
NF-XB is a transcription factor associated with cell survival and the
regulation of components of the inflammatory response, and as such, has been
implicated in many human cancers. RelA is a much-publicized subunit of this
transcription factor and has the ability to confer either activation or repression 
upon its activities.21 ARF induces RelA to associate with histone deacetylase
which can subsequently cause NF-AB to become a repressor. This, in effect, not
only inhibits activation of survival signals, but actively represses it.
c-Myc is a transcription factor associated with the transcription of genes
which stimulate progression of cell division into S-phase. ARF binds to c-Myc and
translocates it to the nucleolus, and thus inhibits Myc induced transcription and 
cell division.6
A study using microarray technology demonstrated that pl9ARF inhibits cell
proliferation in the presence or absence of p53 by inducing Btgl, Btg2, BtgB, and 
Tobl? The BTG/Tob (B-cell Translocation Gene, and Transducer of ErbB-2)
family of proteins are linked to transcriptional repression and anti-proliferation.
Their degradation has been reported to be necessary in order for cells to enter 
Gx.20 BTG2, along with Tobl, have been shown to down-regulate cyclin Dl.30 In
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addition, BTG1-2 have both been shown to co-repress the nuclear estrogen 
receptor, which is involved in proliferation.31
The E2F family is a related group of transcription factors that recognize
similar binding sites and are associated with regulating the cell cycle. They are
required to induce S-phase in order for cells to divide; therefore, inactivation of 
the E2F family inhibits cell division.3 The protein ARF interacts physically with
some members of the E2F family (E2F1, 2, and 3). This causes them to be
sequestered into the nucleolus; alternately, the interaction is followed by 
degradation in the cytoplasm.8 Both events inhibit cell division. Also, when the
concentration of E2F1-3 rises, it causes an increase in ARF protein concentration, 
enhancing ARF's negative regulatory impact.8,32
ARF also interacts with B23, a nucleolar protein that has multiple functions
related to division. B23 has been shown to be one of the components of the
pericentriolar material and has been implicated as affecting centrosome
duplication, sister chromatid segregation, fragmentation of nuclei, as well as 
cytokinesis.33 B23 is also involved in ribosome biogenesis, protein chaperoning, 
and protein trafficking between the nucleus and the cytoplasm.33 ARF binds to
B23 and promotes its ubiquitination and degradation by the cytoplasmic 26S 
proteosome, thereby inhibiting B23 from carrying out these activities.27
Thus, ARF lies at the nexus of two prominent tumor suppressor pathways.
12
p53 and Rb. In addition, it mitigates survival signals, inhibits proliferation and 
adaptation proteins, decreases ribosome biogenesis, and affects the transcription 
of many genes (Fig. 4).
13
Figure 4. Interactions of ARF. ARF interacts with many different proteins and affects their subcellular localization or 
transcriptional activities. p!4 can be transcribed in response to E2F1-3, and can induce the BTG/Tob family.
SIGNIFICANCE
The many interactions of ARF demonstrate its powerful contribution to
inhibiting cancerous growth. As mentioned earlier, breakdowns in this pathway
have been estimated to be at least partially responsible for 40% of all human
cancers. We wished to evaluate how tumorous human cancer cells, known to be
deficient in ARF activity, would react to the re-introduction of p!4ARF. We
additionally set out to evaluate the effects in an isogenic cell line that was
deficient in p53 in order to help elucidate the p53-independent effects of the ARF
protein. This, we expected, would foster a better understanding of the different
outcomes from these two powerful anti-cancer proteins whose effects are usually
interconnected and difficult to separate.
15
APPROACH
In this present study, we decided to investigate the effects of 
overexpression of the p!4ARF protein in the HCT116 cell line and its p53 knockout 
derivative, both in wfraand in vivo. HCT116 is a colorectal carcinoma with an 
active wild type p53 protein.34 One a/fallele in this parent cell line has been 
shown to be inactivated by promoter methylation, while the other allele has been
shown to have two mutations in exon Ip, which is the exon not shared by the 
optional transcript gene at this locus, thus creating a non-active truncated p!4 
protein.5 Therefore, HCT116 cannot produce an active ARF protein. Additionally, 
there is a cell line (HCTmp53) derived from this parent culture that has both of 
the p53 loci replaced with promoterless cassettes.34 This gives two isogenic cell
lines differing only in their p53 status.
We stably transfected the a/fgene into the HCTH6 parent cell line and its
p53 knockout progeny, sequenced the newly incorporated gene and tested it for
protein production. We also ran a clonogenicity study to further test the effects
of ARF overexpression in these cell lines. This was followed by plating the cells




Cell Lines and Cultures
The original cell lines HCT116 and HCTmp53 (p53 -/-) were a kind 
donation from Dr. Bert Vogelstein from Johns Hopkins University.34 All cell 
cultures were maintained at 37 °C with 5% CO2 in DMEM supplemented with
10% FBS and a cell culture antibiotic/antimycotic solution containing 100
units/mL penicillin, 100 (ag/mL streptomycin, and 250 ng/mL amphotericin B
(Sigma, St. Louis, Mo.). The cell lines transfected with pBabePuro were
additionally maintained with puromycin at 1 pg/mL.
Plasmids
Plasmids pcDNAl.lAmpARFlag and pBabePuro were a kind donation from
Dr. Karoly Fatyol. The pcDNAl.lAmpARFlag plasmid was constructed by inserting 
the 426 bp ARFlag sequence (consisting of the 396 bp pl4ARF coding sequence
plus the 30 bp Flag sequence from Sigma fused to the C-terminus) inserted
between the BamHl and the EcoRl sites in the commercially available
(Invitrogen, Carlsbad, Ca.) plasmid pcDNAl.lAmp (Fig. 5A and 5B). The Flag tag
is a commercially available, 30 bp, DNA fragment. It is designed to be added to
the C or N-terminus of DNA sequences in order to differentiate a protein from
others in subsequent experiments. We used the ten amino acid sequence.
translated from the 30 bp DNA sequence, to bind antibodies for our Western Blot
assays.
17
Figure 5A. ARF-bearing transfection plasmid. ARFlag is ligated between the 
BAM HI and ECOR1 sites. The pcDNAl.l/Amp plasmid without the ARFlag is used 
as an empty vector for the clonogenicity experiments.
18
UD
Figure 5B. Puromycin selection plasmid pBabePuro.
Stable Transfections
Ten cm cell culture plates were seeded with approximately 6.0x 106 cells 
and one day later were transfected with plasmids using Fugene 6 Transfection
Reagent from Boehringer Mannheim (Indianapolis, In.). Each 10 cm plate
received 4 jug of the pBabePuro plasmid and 16 j^g of pcDNAl.lARFlag plasmid.
After 48 hours, each of the transfected 10 cm plates was split into 7 plates and
maintained with 1 jig/mL puromycin from that time onward. Forty-one colonies
of the transfected HCT116 cell line, and forty-three colonies of the transfected
HCTmp53 were isolated and evaluated.
Polymerase Chain Reaction and DNA Sequencing
Genomic DNA was purified from our stably transfected HCTmp53 cell line
and PCR was performed on it to insure incorporation of the desired DNA
sequence. PCR was done with the 19 bp primer ARFIagFwd
TACCGAGCTCGGATCCATG (which begins inside the multiple cloning site of the 
vector and overlaps the start codon of the pl4ARF protein coding sequence) and
the 20 bp reverse primer ARFIagRev TCTGCAGAAi iu lACGACC (which starts in 
the multiple cloning site of the vector and finishes on the last five bases of the 
Flag sequence on the C-terminus of the pl4ARF coding sequence). The fragment
produced is 457 base pairs in length including 396 bp from the arfqene coding
sequence, 30 bp from the Flag tag and 31 bp from primer overlap into the
insertion site. The reaction was run in Qiagen Master Mix (Qiagen, Valencia, Ca.)
for 30 cycles and the annealing temperature was 61.6 °C. The PCR fragment was
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purified with the Qiagen MinElute kit and the sequencing was done by the 
University of California at Davis, core facility. Both sequences were performed
using each of the PCR primers separately. We then combined the forward
sequence with the reverse compliment of the reverse sequence and ran a BLAST
query on them from the NCBI web site.
Western Blots
Total cell protein concentration was obtained by running the Dc protein
Assay (Bio-Rad, Hercules, Ca.)) using bovine serum albumin to create the
standard curve. Equal amounts of cellular proteins were run on a Tris-HCI 4-20%
gel (Bio-Rad) and transferred to a PVDF membrane (Amersham Pharmacia
Hybond-P). Anti-flag M2 Monoclonal Antibody (Sigma) was used as the primary
antibody against the ten amino acid Flag sequence fused onto the C-terminus of
ARF. Detection was done using the ECL kit (Amersham Life Sciences, Piscataway,
NJ) containing substrate and anti-mouse Ig linked to horseradish peroxidase,
with the subsequent light captured on Kodak (Rochester, NY) X-Omat AR-5 film
for 30 seconds.
Cell Velocity Assays
The cell velocity assays were done by seeding thirty 10 cm plates with 106 
cells each, approximately 1/30 of a fully confluent plate, which was determined 
by previous counting to contain 3xl07 cells. This was followed by counting the 
cells of three plates with a hemocytometer (Trypan Blue exclusion) every day for
7 days, then every other day for 6 more days. The average of the three daily
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plates were graphed with the standard deviation as cell count versus time and
evaluated. Additionally, the natural log of the cell count versus time was graphed
with the slope of the regression line representing the doubling constant for each 
respective cell line. The cells were maintained at 37 °C in 5% C02 in DMEM
supplemented with 10% FBS and antibiotic/antimycotic solution containing 100
units/mL penicillin, 100 pg/mL streptomycin, and 250 ng/ml amphotericin B
(Sigma). The media was changed every other day.
Clonogenicity Assay
Four 10 cm plates (two HCT116 and two HCTmp53) were plated with 
approximately 6.0xl06 cells and one day later were transfected with 4 pg of
pBabePuro and 16 pg of either the pcDNAl.lAmpARFlag plasmid or the empty
vector pcDNAl.lAMP. The cell lines were transfected using the calcium
phosphate-mediated transfection method (Profection Mammalian Transfection
Systems from Promega, San Luis Obispo, Ca.). Thirty hours after transfection,
the media was drained and 1 mL of trypsin was added to each plate until cells
had detached, then each plate was split into six 10 cm plates. All colonies were
plated in ten cm plates with 10 ml of DMEM and placed under puromycin
selection at 1 pg/mL. This gave us twenty-four plates consisting of six plates of
the HCT116 with the ARFlag vector and six with the empty vector along with six
plates of the p53 knockout version with the ARFlag vector and six more with the
empty vector; all plates included the puromycin vector. After nine days colonies
had formed, and one mL of Thiazol Blue (MTT, 5 mg/mL) was then added to the
22
cell culture media. They were then incubated for an additional 3 hours until the
colonies turned dark. The media was then drained and each plate was
individually placed in the AccuCount 1000 Colony Counter from Biologies
Incorporated (Gainesville, Va.) with the sensitivity set to 8.10 and the colony size
set to 0.1 pm in order for the counter to selectively count colonies with
approximately several hundred cells or more.
Tumor Growth
Tumors were grown in nude/nude mice purchased from Charles River
Laboratories (Wilmington, Ma.). Each mouse received one injection in the upper 
thigh containing 2xl06 cells suspended in 100 pL of DPBS. The tumors were
measured with digital calipers and the volume was calculated by taking the
height times the width times the length and dividing by two (the area of an
oblique sphere inside a cube takes up approximately half its volume when the
diameters of the sphere are equal to the sides of the cube). Tumors were
measured at least every third day once they were large enough to measure and
were grown as large as the mouse could tolerate, up to a maximum of 
approximately 3400 mm3.
There was some natural variability in the amount of time it took the
injections to become a tumorous growth large enough for us to begin
measurements. Therefore, in order to standardize the beginning of each tumor's
growth the following standard was followed: the last measurement prior to 10 
mm3 was considered day one of a tumor's growth, but if the first measurement
23
we obtained was between 10-20 mm3, then growth values were begun on day 2, 
however, if the first measurement exceeded 20 mm3, then the values were 
begun on day 3. All the results were then graphed as tumor volume (cubic 
millimeters) versus time (days).
24
RESULTS
Creating and Characterizing ARE Expressing Cell Lines
The cell lines HCT116 and HCTnrip53 were stably transfected with the
human a/f gene under the control of the CMV promoter, which constitutively 
produces the pl4ARF protein fused to the thirty base pair Flag tag at the C- 
terminus. The Flag tag is used for antibody binding. We were unable to identify, 
by Western blot, any clone from the HCT116 cell line that had detectable ARF
protein expression, even though we were able to produce five colonies out of
forty-one which were stably transfected (data not shown). We isolated forty-
three colonies from the HCTmp53 cell line, and of those, seven had the a/fgene
stably incorporated. Four of the seven had ARF protein expression of varying
intensity (Fig.6). For our further experiments we used the one (#5 in Fig. 6) that
showed the greatest protein expression.
1 2 3 4 5 6 7
Figure 6. ARFlag protein expression. 
FlCTmp53cARF transfected cell lines detected with 
Anti-flag M2 monoclonal antibody raised against 
the Flag tag on the C-terminus of ARF
Polymerase Chain Reaction
The PCR for the ^transfected cell line HCTmp53cARF is shown alongside
the non-transfected cell lines HCT116 and HCTmp53, along with the plasmid
vector containing the a/fgene (Fig. 7); the fragment of interest is 457 base pairs
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in length and is only visible in the positive control plasmid and cell line
HCTmp53cARF.
cBP AMW
Figure 7. PCR of cell lines. MW) 100 bp marker, the 
bright band is 500 bp.
P) Plasmid pcDNAl.lAmpARFIag. A) HCT116 non- 
transfected. B) FICTmp53 non-transfected.
C) HCTmp53cARF stably transfected.
Sequencing and BLAST Analysis
The PCR fragment from Fig. 7C was purified and sequenced and the
resulting information was entered into a human nucleotide Blast query on the
NCBI web site. The results of our search returned a perfect match with the 396 
bp coding sequence from the CDKN2A locus.35 The 30 bp Flag tag was also
found to be correct. This confirmed that the arfqene was stably incorporated
into the HCTmp53 cell line creating cell line HCTmp53cARF. The subsequent
sequence is marked as follows: the double underlined bases are the start and
stop codons, outside of the start and stop codons are the BamHl and EcoRl
insertion sites respectively, followed further to the outside by the adjacent
plasmid DNA sequences, between the start and stop codons is the full-length
ARFlag sequence with the bold lettering denoting the Flag tag. The underlined












We evaluated the expression of the ARF protein from our stably
transfected cell line HCTmp53cARF by Western blot. There was no protein
expression from the original cell lines received or any clones isolated from the
stably transfected HCT116 cell line. However, expression was very good for the
HCTmp53cARF cell line that we selected (Fig. 8). Our band of interest ran
between the 7 kDa and the 18 kDa markers, and was estimated to be in the 16-
17 kDa range. The calculated molecular weight of the ARFlag protein is 15 kDa
due to the addition of the Flag tag. This experiment confirmed that not only did
we have the a/f gene stably incorporated into the genome but also that the
promoter was producing our protein of interest.
A cB
Figure 8. Western blot of protein 
expression from cell lines. Anti-Flag M2 
monoclonal antibody is raised against the 
ten amino acid flag sequence. A) HCTmpSS 
non-transfected. B) HCT116 non- 
transfected. C) HCTmp53cARF transfected 
with a/fgene and expressing ARF protein
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Cell Velocity Assays
The cell velocity assays were done by seeding thirty 10 cm plates with 106 
cells each. This was followed by counting the cells of three plates every day for 7
days, then every other day for 6 more days. The averages of the three daily
plates were graphed along with the standard deviations as cell count versus time
and evaluated. Additionally, the natural log of the cell count versus time was
graphed with the slope of the regression line representing the doubling constant
for each respective cell line. The cell lines are the HCT116 parent cell line, its p53
knockout derivative HCTmp53, and the progeny overexpressing the ARF protein,
HCTmp53cARF.
The cell counts (or In of cell counts) versus hours were graphed and the
resulting graphs are shown in Fig. 9A and 9B respectively. An approximately 24-
hour lag time consistently existed between the plating of the cells and the
beginning of exponential growth. Whether many cells died in the plating process
or whether full growth potential is delayed was not evaluated. However, 24
hours after the plating of the cells, each plate always had less than the number
of cells plated. For this reason growth velocity was calculated from 24 hours
onward. On Fig. 9B a starting point representing the original plating values of 0
hours at 13.82 is placed for reference, but was not used in calculating growth
velocity. Although a large standard deviation is present in many cases, the cell
count averages created a consistent curve.
28














200 250 300 350100 1500 50
Hours
Figure 9A. In vitro cell growth velocities. Each point represents the average number of cells on three plates, along 
with the standard deviation. The growth of each cell type, HCT116, HCTmp53, and HCTmp53cARF, is graphed over 
time.
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Figure 9B. Ln in vitro ce\\ growth velocities. Each point represents the natural log of the average number of cells on three plates, along with 
the standard deviation. The growth of each cell type, HCT116, HCTmp53, and HCTmp53cARF, is graphed over time. The slope of the 
regression line is the doubling constant for each type of cells under these conditions. The doubling time for HCT116 is 19.5 hours in the early 
stage of the graph, and 866 hours in the latter stage. The doubling time for HCTmp53 is 20.8 hours in the early stage, and 154 in the latter 
stage. The doubling time for HCTmp53cARF is 19.6 in the early stage, and 990 in the latter stage.
The early growth potential of the cell lines previous to confluence are
nearly identical with all points falling within the standard deviation of other cell
counts. By 120 hours, the last measurement prior to confluence, the velocity
began to slow and the points start to diverge. This time is therefore the last one
used in the maximum velocity measurement.
In Fig. 9B the natural log of the cell count is graphed versus time. The
slope of the resulting regression line is the doubling constant (k) for the cells
under those conditions. Doubling time of an exponentially growing population is
calculated by In2/k. Therefore, the doubling time of these cells is calculated from
the graph in Figure 9B as follows, HCT116: 19.5 hours prior to confluence and
866 hours at high density; HCTmp53: 20.8 hours and 154 hours respectively;
and HCTmp53cARF: 19.6 hours and 990 hours respectively.
As expected, the cell line with the ARF overexpression slowed dramatically
faster than our other cell lines when they all reached overpopulation. What was
surprising was that the HCT116 cell line, with wild type p53, reached maximum
population faster than its p53-/- derivative. However, during the later stages of
the experiment the HCT116 cell line slowed to a greater degree while the
HCTmp53 cell line continued to divide more rapidly. This might be due to the fact
that p53 is an integrator of cellular signaling and in some instances, without ARF
to increase its concentration dramatically, may actually aid the cells in adapting
to a changing environment. By the end of the thirteen days (just over 300
hours), the HCTmp53 cell line reaches the same level of population density as
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the p53 wt cell line, approximately 9xl07, while the cell line overexpressing the
ARF protein plateaued at a lower population density than either of the non- 
transfected cell lines, approximately 6xl07. A repeated measures ANOVA
statistical analysis was done on the data from Figure 9B. No statistical difference
was seen in the growth velocities prior to confluence (below 130 hours), but a
statistically significant difference (pcO.OOl) was seen between the groups in the
high density set above 200 hours.
Clonogenicity Assay
The clonogenicity experiments are a transient transfection study that was
done to assess the effects of the ARF protein on colony formation and cell
survival. This study was run with the expectation that the plated cells which had
been transfected with the ARF-bearing vector would produce fewer colonies
when compared to the empty vector set, due to its antiproliferative effects on
cells. This was indeed observed with both the HCT116 and the HCTmp53 cell
lines (Fig. 10). The HCT116 cell line which received the empty vector had on
average 3146 +/- 384 colonies, while the one receiving the ARFlag vector had
only 49 +/- 5 colonies, an over 98% reduction in the number of colonies. The
HCTmp53 cell line which received the empty vector had on average 1962 +/-
350 colonies, while the one receiving the ARFlag vector had 333 +/- 30 colonies.
an over 83% reduction. As expected, in both cases the cell lines receiving the
empty vector had far more colonies than the ones receiving the ARFlag vector.
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Figure 10. Clonogenicity of HCT116 and HCTmp53 cell lines. The number of colonies of the HCT116 cell line was 
decreased from 3146 colonies to 49 colonies by the addition of the ARFlag vector, a 98% reduction. The number of 
colonies of the HCTmp53 cell line was decreased from 1962 colonies to 333 colonies by the addition of the ARFlag 
vector, an 83% reduction.
vector, fared better than the HCTmp53, which also received the empty vector.
Along with the cell velocity study, this is the second indication that p53 may
increase cell viability in some instances. This may possibly be due to intact p53
acting as an integrator of cellular signaling, which at low concentrations may aid
in cell survival in some instances. The HCTmp53 cell line receiving the ARFlag
vector had a much higher survival rate than the HCT116 counterpart. This is
most likely due to the ARF protein causing an increase in the concentration of
available p53, followed by a subsequent increase in apoptotic and senescent
signaling in the HCril6 cell line.
A statistical analysis was performed on the clonogenicity assay using a
2x2 ANOVA. The repeated colony counts were ranked in order to meet the
assumptions of the parametric tests. A significant interaction between each of
the cell lines and ARF existed (pcO.OOl), showing the ARF effect as being
greater than the p53 effects. This, in effect, is saying that the odds of this
observation happening by chance are one in one thousand, and that in this
system, ARF exhibited a stronger effect than did p53.
Tumors
Since pl4ARF has antiangiogenic activities, such as the downregulation of
HIF-1, as well as antiproliferative activities, we expected that tumors expressing
the ARF protein would grow slower than those without. Neither of our non-
transfected cell lines produces an active ARF protein, so it was anticipated that
the HCTmp53cARF cell line, which had been shown to produce the ARF protein,
34
would grow slower than either of the non-transfected cell lines, and this was
indeed the case. Our results show a marked and dramatic reduction in tumor
potential when ARF is expressed in these cell lines (Fig. 11). The non-transfected
tumors grew at approximately the same rate as the fastest of our transfected 
ones, but the significant portion of both groups is far removed from each other.
Fourteen mice were injected with the HCT116 cell line, and of those 
thirteen developed tumors that grew to at least 600 mm3. Eleven of them grew 
to greater than 1000 mm3, with most of the eleven far above, with the highest 
growing to approximately 3400 mm3.
Of fourteen mice injected with the HCTmp53 cell line, ten developed
tumors. All of these tumors grew to a large size, with the smallest exceeding 
1800 mm3, and the largest reaching approximately 3400 mm3.
Twelve mice were injected with the HCTmp53cARF cell line, and of those
all twelve developed tumors. Two different mice each developed multiple tumors
that would ultimately grow together, so they were not included. One other
mouse had a single tumor growing initially, and then a second tumor developed.
We measured the first tumor until it became impossible to collect accurate
information, and after that, it too had to be excluded from further
measurements. Therefore, ten mice had HCTmp53cARF tumors that were
measured until growth potential had been realized.
Tumors have very heterogeneous growth population dynamics due to
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Figure 11. Tumor growth velocities. Growth velocities from tumors initiated by injection of cell lines HCT116, 
HCTmp53, and HCTmp53cARF into mice.
pattern in growth velocities was anticipated. What was not expected was that 
the HCT116 and HCTmp53 cell lines would grow at about the same rate and
therefore have virtually identical spread patterns. We predicted that the
HCTmp53 cell line would grow faster due to the absence of p53, but our
observations did not support this expectation. Other reports on implantation of
these two cell lines in mice showed mixed results. For example, one report using 
these same mice reported a marked difference in size 29, while another report
using SCID (severe combined immunodeficiency) mice showed little or no 
difference.36 Perhaps a larger study group and robust statistical analysis is
needed to examine this phenomenon.
A statistical analysis of the tumor growth potential was performed using a
one-way repeated measures ANOVA. Since tumors were standardized to
measure growth velocity, a linear extrapolation from known points was
performed to fill in any missing values. A statistically different growth rate among
the three groups existed (p<0.0001). This means that the odds are less than one
in ten thousand that this configuration happened by chance.
We excised all ten of the mouse HCTmp53cARF tumors and ran a PCR
(Fig. 12A) and a Western Blot (Fig. 12B) on each of the tissue samples to insure
that our gene of interest was still present and expressing protein. We found that 
the pl4ARF gene was present in all cases and expressing protein in nine of the
ten tumors. On more than one occasion, during our previous experimentation.
the p!4ARFIag vector had been silenced in our stably transfected cell line
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HCTmp53cARF, even though it could be shown by PCR that it was still present,
so loss of expression here is not an anomaly. The time point when expression
was lost is not known, as all tumors were injected from one syringe derived from
one 10 cm culture dish. The tumors with the highest protein expression in Figure
12B (#5, 6, and 9) are delineated on the graph in Figure 11 as red +, x, and -
respectively. Tumor number 10, which shows no detectable ARF expression, is
delineated with a black box outside the red squares. The three tumors that grew
the fastest are shown is Figure 12B with their numbers underlined. Thus, there
does not appear to be a high correlation here with the amount of protein
produced and the size of the tumors.
Figure 12A. PCR of tumors from HCTmp53cARF cell line. MW is 
the molecular weight marker with the bright band at 500 bp. P 
is the ARFlag plasmid and 1-10 are the ten tumors generated 
from cell line HCTmp53cARF. The band of interest is 457 bp in 
length.
7 8 9 105 62 3
Figure 12B. Western Blot of tumors from FICTmp53cARF cell line. Proteins 
were detected with the Anti-flag M2 monoclonal antibody raised against 
the flag-tag expressed on the C-terminus of ARF.
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DISCUSSION
Our results indicate that the overexpression of p!4ARF in tumor cells
lacking a functioning ARF protein causes decreased growth potential for cells
both in vitro and in vivo. These effects are more striking in the cell line with
active p53, but were still apparent in the p53 negative counterpart.
The clonogenicity study demonstrates that the ARF protein causes an
enormous decrease in cell viability when compared to a control group inoculated
with an empty vector. In the presence of p53, the number of HCT116 cell line
colonies was decreased 98.4% (3146 colonies down to 49) by transient 
transfection with pl4ARF. This is a dramatic reduction, but not altogether
unexpected, given its p53-dependent and independent affects. One highly
publicized effect of p53 is to steer cells towards apoptosis or senescence, and
ARF has been shown to increase the p53 concentrations dramatically through its
interaction with the p53 negative regulator MDM2. In the p53 negative cell line
(HCTmp53) the cells receiving the ARFlag vector had a reduced colony count of
83.0% (1962 colonies down to 333), not as pronounced as the p53 positive cell
line's decline, but a very significant decrease nonetheless. This reduction can 
only be attributed to effects independent of p53, therefore pl4ARF is
demonstrating a powerful and lethal impact on the cells' viability outside of the
well-characterized p53 pathway. Since pl4 has been shown to have many
independent effects, as well as being a major factor in increasing the
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concentration of p53, a decrease in the number of colonies in the presence of
ARF is expected regardless of their p53 status.
We selected forty-one clones of the HCT116 cell line from our stable
transfection experiment, of which five had incorporated the ARFlag vector into
their genome. None of them could be shown by Western Blot to produce any
detectable amount of the ARF protein. This led us to speculate that the elevated
levels of ARF protein, in cooperation with p53, may be lethal to these cells. We
also selected forty-three clones of the HCTmp53 cell line, and of those, seven
had the ARFlag vector stably incorporated into the DNA. Four of these had
differing but detectable levels of the ARF protein.
We selected almost the same number of clones from both the HCT116
and HCTmp53 cell lines. We established that each cell line had approximately the
same percentage of clones that incorporated only the puromycin selection
vector. However, the HCT116 cell line had fewer clones that incorporated the
ARFlag vector, and none of these displayed a detectable quantity of protein
production. This suggests that the differences in the cell line outcomes may be
due to the p53 activity. For example, it may be that any p53 positive clone,
which also produced the ARF protein, died or became quiescent, while those
lacking p53 were free to express ARF.
The in vitro cell velocity assays produced some expected and some
unexpected results. The expected result was that the ARF protein would inhibit
cell growth at high-density populations, and the p53 negative cell line would
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divide best under these circumstances as well. What was not expected was that
all three cell lines, regardless of their p53 or ARF status, would grow at almost
the exact same velocities at low concentrations. We expected that ARF's
antiproliferative effects, such as its inhibition of ribosome biogenesis, cell cycle
transcription factors, DNA unwinding, and its activation of antiproliferative genes.
would cause cell line HCTmp53cARF to grow much slower in any instance, but
slower growth was seen only at high population densities. We also expected that
the HCT116 cell line with the wt p53 would grow slower than its p53 negative
counterpart HCTmp53, due to the presence of the powerful apoptotic and
senescence protein p53. Nevertheless, at low populations they all grew at
approximately the same rate, and only at high-density populations did we begin 
to observe the expected differences. Another investigation supported our result 
that the HCT116 and HCTmp53 cell lines grow at approximately the same rate.29
This led us to speculate that p53 may not be very active in the absence of
ARF, which is its main known contributor to increased concentration. It may also
be that cellular signals, stemming from low population density, are rendering the
p53 inactive toward slowing the growth potential; or perhaps the cellular
signaling is able to overcome the effects of p53 if it is kept at a low
concentration. Essentially a similar argument can be made for the ARF protein
effects being overwhelmed by the low population density cell signals calling for
division.
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Other explanations for ARF having little or no impact on dividing potential
in the low population density portion of our experiments include the possibility
that this phenomenon is clone specific, tissue specific, or even that some
negative control on ARF activity exists outside of the reported transcriptional
control.
We observed that the maximum population for these cells in a 10 cm dish 
is approximately 9xl07 cells (three times confluence) for the non-transfected cell 
lines and about 6xl07 cells (two times confluence) for the ARF producing cell 
line. At high-density populations the division of the HCT116 cell line plateaued, 
having driven itself directly to almost maximum population rather quickly. The
HCTmp53 cell line was still dividing well, but had lagged behind the HCT116 cell
line in total population from the time it reached confluence until the very end of
the experiment. The HCTmp53cARF cell line mirrored the HCTmp53 cell line until
it achieved close to maximum density, then division tapered off while the non- 
transfected cell line continued to divide. The pl4ARF had no apparent effects on
division until the cells reached a specific density. At that point the division in the
ARF-bearing cells leveled off while the HCTmp53 cell line continued to divide, as
if the cellular signaling was no longer able to overcome the ARF signal.
We can only speculate on why the p53 positive cells reached maximum
population the fastest. Perhaps the low amounts of p53, acting as an integrator
of the cellular signaling, confers an adaptability to the cell line enabling it to be
more flexible to the dynamic conditions as the density changes over time.
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For the tumors we grew in nude mice, our results were once again
partially expected and partially unexpected. We had expected that the tumors
grown from the HCTmp53cARF cell line would grow substantially slower than the
tumors grown from the non-transfected cell lines, and this was indeed the case.
What we had not expected was that the tumors developed from cell lines
HCT116 and HCTmp53 would grow at approximately the same rate. Experiments
run on these same mice, with the HCT116 and HCTmp53 cell lines, reportedly
showed a marked increase in tumor size in the p53-/- cell line HCTmp53; 
however, our experiments did not support this finding.29 Another study using
SCID (severe combined immunodeficiency) mice reported a very low difference 
in tumor size when comparing tumors grown from these two cell lines.36 Since
our experiments were more similar to the report using the same mice, and given
the nature of interactions of ARF, we had expected that there would be some
difference in tumor growth, but it could not be established from our results.
Each cell line's tumors were graphed and what emerged was a spread
pattern resulting from the differences in individual tumor growth velocities. Both
of the non-transfected cell lines velocity patterns were interspersed. Three out of
ten tumors resulting from the transfected cell line grew with velocities similar to
the non-transfected cell lines, while seven had significantly reduced tumor
growth potential.
There did not appear to be a significant correlation between the quantity
of the ARF protein produced and the growth velocity of the individual tumors.
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This may indicate that only a particular concentration of ARF is needed to carry
out all its activities. However, overall, there was a significant reduction in growth
potential for the HCTmp53cARF cell line tumors as compared to the other two
non-transfected cell line tumors HCT116 and HCTmp53. One slow-growing tumor
showed no detectable quantity of ARF, and this may indicate that even a very
minute amount of p!4 is able to mitigate growth potential.
One unexpected observation was that p53, in both the clonogenicity
experiments and the cell velocity assays, may confer some growth benefits in the
absence of the ARF protein, particularly under low population density conditions.
We feel this could at least be partially due to p53 being at a low concentration
without the presence of ARF. p53 is modified in many ways by the signal
transduction pathways, for example, it can be phosphorylated at several
residues, as well as ubiquitinated and sumoylated. These pathways may serve to
activate p53 to coordinate events not associated with apoptosis and senescence.
We found little difference in the p53 positive and p53 negative cell lines in
the absence of ARF, both in the cell velocity assays and in the tumors grown.
Perhaps if the cell velocity assays had been run longer we may have seen
something different. It is also possible that careful analysis of larger groups of
tumors would show some difference in growth characteristics, however, we did
not set out to evaluate these differences.
Our main focus was the effect of ARF. In all our experiments we saw
dramatic results. In the cell velocity assays the cell grew to lower densities. In
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the clonogenicity experiments the growth potential was reduced by either 98 or
83%, and in the tumor growth velocity experiments the tumors grew significantly
slower. All these results testify to the importance and strength of this diverse
protein.
It also bears mentioning that we were unable to produce a stable cell line
which had both p53 and ARF activity. This cell line could have provided a wealth
of information from cross-analysis with our other groups. However, it may be
that high concentrations of ARF, in conjunction with active p53, are not
compatible in this or similar types of cancerous cell lines. This is in and of itself a
significant piece of information and may be a valuable tool in the future to
finding a cure for many cancers.
Overall, our results indicate that p!4ARF has a strong p53 independent
effect. When coupled with p53, the synergistic effect is even more impressive. In
the HCT116 cell line, however, it appeared as if the ARF contribution had a
stronger effect. This could be due to the fact that ARF was being produced
constitutively, while p53 was under normal cellular regulation. Nevertheless,
under these conditions, p!4 appears to have a stronger effect.
Our model for ARF activity is that it is a very powerful antiproliferative
protein, both in the presence or absence of p53. Our results also suggest that in
some cases it is more effective than p53. Furthermore, at low population
densities it appears less effective than at high densities, at least in the absence
of p53. Given all of the proteins that ARF is reported to affect, and the fact that
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it is induced in response to a host of mitogenic stimuli, it seems likely that there
must be some mechanism to override its effects. If cells calling for division up-
regulate the inhibition signal, it is logical that there is a system in place to
mitigate the antiproliferative response.
Much future research on ARF will be required to determine its full effects
on cellular regulation. Whether the effects of ARF at low-density populations are
specific to the single clone we selected, or tissue specific, needs to be better
understood. Also, the possibility that there are other post-transcriptional actions
that modify its activity needs to be investigated more fully. Understanding why
ARF oligomerizes with itself, dependent on its cysteine residues, might prove a
very fruitful endeavor. There is little information on the temporal and spatial
distribution of ARF and its activities in normal and non-dividing cells. It has been
shown that ARF concentrates predominantly in the nucleolus, and that it is 
eliminated under normal growth conditions between metaphase and Gi.37 How 
exactly this happens, however, is not yet known. Most research is devoted to
understanding ARF's binding partners and activating signals, and rightly so.
However, much could be learned from investigating the differences and
similarities that exist between non-dividing cells and dividing cells with regard to
ARF's transcription and regulation. For example, how a normal dividing cell deals
with the ARF signal could prove a valuable tool in understanding how its activity
can be overcome; and how ARF is eliminated from cells in early Gi may provide a
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means to prevent its degradation in cancerous cell lines, and thereby inhibit
proliferation.
Questions that need to be answered include: Where and when is ARF
present in normal cells? Why does a high concentration of ARF in low-density
populations seem to have little or no effect? What mechanism does a cell use to
overcome ARF expression induced by proliferation signals? How does ARF
disappear between metaphase and Gi? Does ARF have other active domains?
Does ARF only serve to bind and translocate proteins? Are the ARF cysteine
residues used as an intra-molecular bridge and/or as a way to inactivate it? What
is the purpose of ARF self-oligomerization? There is important information on
ARF hidden in the answers and much research left to be done in order to more
fully understand this potent and active protein.
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